



## PRESS RELEASE

*This information was submitted for disclosure on 23 January 2018 at 08.45 (cet).*

## **Presentation of Probi's Q4 report 2017**

**Probi's report for the fourth quarter 2017 will be published on Thursday, 25 January at 8.00 a.m. CET**

In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Peter Nählstedt and CFO Jörn Andreas will present and comment on the report. The presentation and presentation material can be obtained via [www.probi.se](http://www.probi.se) or <https://tv.streamfabriken.com/probi-q4-2017>

The presentation can also be followed via a telephone conference on the following telephone number:  
Sweden: +46 8 56 64 26 97  
UK: +44 20 30 08 98 07  
US: +1 85 58 31 59 46

After the presentation, conference participants will be able to ask questions. Questions can also be asked via the audiocast.

An on-demand version of the presentation will be available at the addresses given above following the presentation.

### **FOR FURTHER INFORMATION, CONTACT:**

Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23, e-mail: [peter.nahlstedt@probi.com](mailto:peter.nahlstedt@probi.com)  
Jörn Andreas, CFO, Probi, tel +46 46 286 89 41, e-mail: [jorn.andreas@probi.com](mailto:jorn.andreas@probi.com)

### **ABOUT PROBI**

*Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2016, Probi had net sales of MSEK 444. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at [www.probi.com](http://www.probi.com).*